156 related articles for article (PubMed ID: 12364422)
1. Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism.
Palomba S; Orio F; Morelli M; Russo T; Pellicano M; Nappi C; Mastrantonio P; Lombardi G; Colao A; Zullo F
J Clin Endocrinol Metab; 2002 Oct; 87(10):4476-81. PubMed ID: 12364422
[TBL] [Abstract][Full Text] [Related]
2. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial.
Palomba S; Russo T; Orio F; Tauchmanovà L; Zupi E; Panici PL; Nappi C; Colao A; Lombardi G; Zullo F
Hum Reprod; 2002 Dec; 17(12):3213-9. PubMed ID: 12456626
[TBL] [Abstract][Full Text] [Related]
4. Lipid, glucose and homocysteine metabolism in women treated with a GnRH agonist with or without raloxifene.
Palomba S; Russo T; Orio F; Sammartino A; Sbano FM; Nappi C; Colao A; Mastrantonio P; Lombardi G; Zullo F
Hum Reprod; 2004 Feb; 19(2):415-21. PubMed ID: 14747190
[TBL] [Abstract][Full Text] [Related]
5. Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone.
Palomba S; Morelli M; Di Carlo C; Noia R; Pellicano M; Zullo F
Fertil Steril; 2002 Jul; 78(1):63-8. PubMed ID: 12095492
[TBL] [Abstract][Full Text] [Related]
6. Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas.
Palomba S; Orio F; Falbo A; Oppedisano R; Tolino A; Zullo F
Fertil Steril; 2008 Jul; 90(1):165-73. PubMed ID: 18001721
[TBL] [Abstract][Full Text] [Related]
7. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
[TBL] [Abstract][Full Text] [Related]
8. Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study.
Palomba S; Orio F; Morelli M; Russo T; Pellicano M; Zupi E; Lombardi G; Nappi C; Panici PL; Zullo F
J Clin Endocrinol Metab; 2002 Aug; 87(8):3603-8. PubMed ID: 12161482
[TBL] [Abstract][Full Text] [Related]
9. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
10. Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata.
Nakayama H; Yano T; Sagara Y; Kikuchi A; Ando K; Wang Y; Watanabe M; Matsumi H; Osuga Y; Momoeda M; Taketani Y
Gynecol Endocrinol; 1999 Dec; 13(6):382-9. PubMed ID: 10685331
[TBL] [Abstract][Full Text] [Related]
11. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women.
Jirecek S; Lee A; Pavo I; Crans G; Eppel W; Wenzl R
Fertil Steril; 2004 Jan; 81(1):132-6. PubMed ID: 14711556
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of ipriflavone in preventing adverse effects of leuprolide.
Somekawa Y; Chiguchi M; Ishibashi T; Wakana K; Aso T
J Clin Endocrinol Metab; 2001 Jul; 86(7):3202-6. PubMed ID: 11443189
[TBL] [Abstract][Full Text] [Related]
13. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.
Smith MR; Fallon MA; Lee H; Finkelstein JS
J Clin Endocrinol Metab; 2004 Aug; 89(8):3841-6. PubMed ID: 15292315
[TBL] [Abstract][Full Text] [Related]
14. [A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women].
Zheng SR; Wu YY; Zhang ZL; Yang X; Hui Y; Zhang Y; Chen SL; Den WH; Liu H; Ekangaki A; Stocks J; Harper K; Liu JL
Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):226-9. PubMed ID: 12885371
[TBL] [Abstract][Full Text] [Related]
15. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
[TBL] [Abstract][Full Text] [Related]
16. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M
J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148
[TBL] [Abstract][Full Text] [Related]
17. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
[TBL] [Abstract][Full Text] [Related]
18. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.
Zheng S; Wu Y; Zhang Z; Yang X; Hui Y; Zhang Y; Chen S; Deng W; Liu H; Ekangaki A; Stocks J; Harper K; Liu J
Chin Med J (Engl); 2003 Aug; 116(8):1127-33. PubMed ID: 12935394
[TBL] [Abstract][Full Text] [Related]
19. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.
Baytur YB; Ozbilgin K; Cilaker S; Lacin S; Kurtul O; Oruc S; Koyuncu FM
Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):94-103. PubMed ID: 16973256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
